Molecular imaging of thyroid and parathyroid diseases.

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM

Expert Review of Endocrinology & Metabolism Pub Date : 2024-07-01 Epub Date: 2024-06-18 DOI:10.1080/17446651.2024.2365776

Petra Petranović Ovčariček, Letizia Calderoni, Alfredo Campenni, Stefano Fanti, Luca Giovanella

{"title":"Molecular imaging of thyroid and parathyroid diseases.","authors":"Petra Petranović Ovčariček, Letizia Calderoni, Alfredo Campenni, Stefano Fanti, Luca Giovanella","doi":"10.1080/17446651.2024.2365776","DOIUrl":null,"url":null,"abstract":"Introduction: Molecular imaging of thyroid and parathyroid diseases has changed in recent years due to the introduction of new radiopharmaceuticals and new imaging techniques. Accordingly, we provided an clinicians-oriented overview of such techniques and their indications.Areas covered: A review of the literature was performed in the PubMed, Web of Science, and Scopus without time or language restrictions through the use of one or more fitting search criteria and terms as well as through screening of references in relevant selected papers. Literature up to and including December 2023 was included. Screening of titles/abstracts and removal of duplicates was performed and the full texts of the remaining potentially relevant articles were retrieved and reviewed.Expert opinion: Thyroid and parathyroid scintigraphy remains integral in patients with thyrotoxicosis, thyroid nodules, differentiated thyroid cancer and, respectively, hyperparathyroidism. In the last years positron-emission tomography with different tracers emerged as a more accurate alternative in evaluating indeterminate thyroid nodules [18F-fluorodeoxyglucose (FDG)], differentiated thyroid cancer [124I-iodide, 18F-tetrafluoroborate, 18F-FDG] and hyperparathyroidism [18F-fluorocholine]. Other PET tracers are useful in evaluating relapsing/advanced forms of medullary thyroid cancer (18F-FDOPA) and selecting patients with advanced follicular and medullary thyroid cancers for theranostic treatments (68Ga/177Ga-somatostatin analogues).","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2024.2365776","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Molecular imaging of thyroid and parathyroid diseases has changed in recent years due to the introduction of new radiopharmaceuticals and new imaging techniques. Accordingly, we provided an clinicians-oriented overview of such techniques and their indications.

Areas covered: A review of the literature was performed in the PubMed, Web of Science, and Scopus without time or language restrictions through the use of one or more fitting search criteria and terms as well as through screening of references in relevant selected papers. Literature up to and including December 2023 was included. Screening of titles/abstracts and removal of duplicates was performed and the full texts of the remaining potentially relevant articles were retrieved and reviewed.

Expert opinion: Thyroid and parathyroid scintigraphy remains integral in patients with thyrotoxicosis, thyroid nodules, differentiated thyroid cancer and, respectively, hyperparathyroidism. In the last years positron-emission tomography with different tracers emerged as a more accurate alternative in evaluating indeterminate thyroid nodules [¹⁸F-fluorodeoxyglucose (FDG)], differentiated thyroid cancer [¹²⁴I-iodide, ¹⁸F-tetrafluoroborate, ¹⁸F-FDG] and hyperparathyroidism [18F-fluorocholine]. Other PET tracers are useful in evaluating relapsing/advanced forms of medullary thyroid cancer (¹⁸F-FDOPA) and selecting patients with advanced follicular and medullary thyroid cancers for theranostic treatments (⁶⁸Ga/¹⁷⁷Ga-somatostatin analogues).

查看原文本刊更多论文

甲状腺和甲状旁腺疾病的分子成像。

导言：近年来，由于新放射性药物和新成像技术的引入，甲状腺和甲状旁腺疾病的分子成像发生了变化。因此，我们以临床医生为导向概述了这些技术及其适应症：我们在 PubMed、Web of Science 和 Scopus 上进行了文献综述，没有时间或语言限制，使用了一个或多个合适的检索标准和术语，并筛选了所选相关论文中的参考文献。截至 2023 年 12 月（含 2023 年 12 月）的文献均包括在内。对标题/摘要进行了筛选，删除了重复的文章，并检索和审查了其余可能相关文章的全文：甲状腺和甲状旁腺闪烁扫描仍然是甲状腺毒症、甲状腺结节、分化型甲状腺癌和甲状旁腺功能亢进患者不可或缺的检查项目。近年来，使用不同示踪剂的正电子发射断层扫描技术已成为评估不确定甲状腺结节[18F-氟脱氧葡萄糖（FDG）]、分化型甲状腺癌[124I-碘化物、18F-四氟硼酸盐、18F-FDG]和甲状旁腺功能亢进[18F-氟胆碱]的更准确的替代方法。其他 PET 示踪剂可用于评估甲状腺髓样癌的复发/晚期形式（18F-FDOPA），以及选择晚期滤泡性甲状腺癌和甲状腺髓样癌患者进行治疗（68Ga/177Ga-somatostatin 类似物）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Endocrinology & Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

4.80

自引率

0.00%

发文量

期刊介绍： Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.